Lixivaptan Approval Status
Lixivaptan is an investigational selective vasopressin 2 receptor antagonist for the treatment of symptomatic hypervolemic and euvolemic hyponatremia.
In November 2012, Cornerstone Therapeutics Inc. announced the receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA), advising the company that the New Drug Application (NDA) for lixivaptan had not been approved.
Development Status and FDA Approval Process for lixivaptan
|Nov 1, 2012||Cornerstone Therapeutics Receives Complete Response Letter From the FDA for Lixivaptan|
|Sep 13, 2012||Cornerstone Therapeutics Provides Update on FDA Advisory Committee Discussion of Lixivaptan|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.